Welcome to our dedicated page for Ventyx Biosciences news (Ticker: VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences stock.
Ventyx Biosciences, Inc. news covers the company’s history as a Nasdaq-listed clinical-stage biopharmaceutical issuer developing oral small-molecule therapies for autoimmune, inflammatory, cardiovascular and neurodegenerative diseases. Recurring updates include NLRP3 inhibitor programs such as VTX2735 for recurrent pericarditis and VTX3232 for inflammation-related cardiovascular and neurodegenerative indications, as well as inflammatory bowel disease candidates tamuzimod (VTX002) and VTX958.
Company announcements also address clinical data, trial planning, advisory board changes, investor conference participation, operating and financial results, material agreements, shareholder voting matters and the completed acquisition that made Ventyx a wholly owned subsidiary of Eli Lilly and Company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.